12.13
Van intraveneuze infusie naar orale dosering: conversiemethoden
De ontwikkeling van formuleringen met verlengde afgifte heeft de overgang van intraveneuze naar orale toediening vergemakkelijkt en biedt een praktisc…
The availability of extended-release formulations has enabled the conversion from IV infusions to oral medications.
Discontinuing the IV infusion decreases the plasma drug concentration by first-order elimination kinetics.
Oral dosing must counteract this decline to achieve a new steady-state concentration.
For patients stabilized on IV infusion, two methods are used to calculate oral dosage regimens.
The first method assumes that the steady-state plasma drug concentration after IV infusion matches the desired average steady-state plasma drug concentration after multiple oral dosing. Here, the average steady-state concentration depends on the drug’s salt form, fractional bioavailability, clearance, and dosing rate.
An IV infusion of aminophylline at 34 mg per hour corresponds to an oral theophylline dose of 28.9 mg per hour. Over 24 hours, this yields a total daily theophylline dose of about 700 mg.
The second method equates the IV infusion rate to the desired oral dosing rate. Here, the oral dosing rate can be calculated by simply multiplying the total daily IV dose by the salt form of the drug.
View the full transcript and gain access to JoVE Core videos
Q1: Why is converting from IV infusion to oral medication necessary?
Extended-release formulations enable safer, more convenient patient transitions from IV to oral therapy while maintaining therapeutic drug levels. This shift improves quality of life by allowing self-administration at home rather than requiring continuous hospital infusions. The conversion preserves efficacy and prevents adverse effects through careful pharmacokinetic management.
Q2: What happens to drug concentration when an IV infusion is discontinued?
Discontinuing IV infusion causes plasma drug concentration to decline following first-order elimination kinetics. Oral dosing must be carefully calculated to counteract this drop and establish a new steady state. Extended-release formulations help by allowing steady drug release over time, mimicking constant levels achieved with IV infusions.
Q3: What is the first method for calculating oral dosage during IV-to-oral conversion?
The first method matches the steady-state plasma concentration achieved with IV infusion to the desired average concentration with oral dosing. This calculation incorporates the drug's salt form, fractional bioavailability, clearance, and dosing rate. For example, an IV aminophylline infusion of 34 mg/hour converts to approximately 700 mg daily oral theophylline dose.
Q4: How does the second conversion method differ from the first?
The second method directly equates the IV infusion rate to the desired oral dosing rate by multiplying the total daily IV dose by the drug's salt form. While simpler to apply, this approach does not account for differences in bioavailability or dosing schedule effects, potentially leading to inaccuracies in maintaining therapeutic drug levels compared to the first method.
Q5: What parameters must be considered when calculating oral dosage from IV infusion?
Critical parameters include the drug's salt factor, fractional bioavailability, clearance rate, and desired dosing frequency. For theophylline with 100% bioavailability, a 28.9 mg/hour IV infusion rate yields approximately 700 mg daily oral dose, often divided into two 350 mg controlled-release doses administered every 12 hours to maintain therapeutic levels.
Q6: Why are extended-release formulations important for IV-to-oral conversion?
Extended-release formulations enable steady drug release over extended periods, mimicking constant plasma levels achieved with IV infusions. This sustained delivery maintains therapeutic drug concentrations throughout the dosing interval, reducing fluctuations and improving patient compliance compared to immediate-release oral medications requiring frequent dosing.
Q7: What role does bioavailability play in converting IV to oral dosing?
Bioavailability determines how much oral drug reaches systemic circulation compared to IV administration. The first conversion method accounts for bioavailability differences through the fractional bioavailability factor, ensuring equivalent therapeutic exposure. Ignoring bioavailability, as in the simpler second method, may result in subtherapeutic or toxic drug levels.